INDGN

Concall Schedule Concall Date: 13 November 2026 Concall Time: In Person Meeting with Mirabilis Investment Trust

Management Guidance & Outlook - Organic growth rate in FY27 expected to be stronger than FY26, with H2 stronger than H1. - On track to achieve quarterly EBITDA margins of 19%+ by Q4 FY27 driven by operating leverage, workforce transformation, and productivity gains. - Meaningful revenue true-up and margin uplift from the $10M ACV outcome-based contract expected in Q4 FY27. Financial Performance & Key Metrics - Q2 revenue reached INR 11,223 million (US$ 117.5M), up 39.5% YoY and 5.6% QoQ in INR terms. - Q2 EBITDA stood at INR 1,873 million (up 32% YoY) with margins at 16.7%, absorbing ~150 bps impact from annual wage hikes. - Trailing 12-month revenue per employee improved to US$ 79,600 vs US$ 69,000 a year ago, aided by output-based pricing and GenAI platforms. - Active clients rose to 107 (up by 31 YoY); $1M+ clients increased to 59 and $10M+ clients grew to 13. Growth Drivers & Deal Wins - Signed 9 deals with ACV >$1M, including 3 large deals (one $5M+ and two in the $3M–$5M range). - Broadening uptake of GenAI-led Agentic AOR and Tectonic models across top pharmaceutical clients. - BioPharm completed one year post-acquisition, realizing ~$1.5M in annual cost savings with strong cross-sell traction.